2021 ASH Annual Meeting
Updates in hematologic oncology research and blood cancers management presented at the 63rd American Society of Hematology Annual Meeting & Exposition
Advertisement
Advertisement
Teclistamab produced meaningful and durable responses in patients with heavily pretreated relapsed or refractory multiple ...
A recent study of brexu-cel supports its use for the treatment of MCL.
Pivotal trials that supported FDA approval of CAR T-cell therapies had low proportions of Black patients enrolled.
Researchers explored whether population-based screening for MGUS could increase the frequency of patients with multiple ...
Frontline treatment of ibrutinib plus venetoclax induced deep responses in patients with previously untreated CLL.
Circulating tumor DNA accurately reflects tumor burden and may serve as a useful clinical biomarker for risk and outcome in ...
According to results presented at ASH 2021, the triplet combination of magrolimab plus azacitidine and venetoclax was safe.
Jacob Laubach, MD, MPP, from Dana-Farber Cancer Institute, shares his thoughts.
Dr. Laubach, from Dana-Farber Cancer Institute, reviews follow-up data from the phase II GRIFFIN trial.
Dr. Daver shares results from a phase I/II study evaluating the addition of the anti-CD47 antibody magrolimab.
Induction and consolidation therapy with the combination induced responses in 98% of patients with newly diagnosed AML.
Three-quarters of evaluable patients experienced complete cytogenetic complete response.
Researchers shared a new single-cell multi-omic analysis of the genetic, cellular, and molecular landscape of TP53-driven.
Noopur Raje, MD, says the future of BCMA-directed CAR T-cell therapies may lie with next-generation agents such as bb21217.
Frederick Locke, MD, from Moffitt Cancer Center, shares findings from the ZUMA-7 trial, which evaluated the chimeric antigen ...
Noopur Raje, MD, discusses the safety and efficacy results of the CRB-402 trial.
The chimeric antigen receptor (CAR) T-cell therapy lisocabtagene maraleucel (liso-cel) significantly improved event-free ...
Ibrutinib and venetoclax demonstrated superior MRD responses in older/unfit patients with previously untreated CLL.
97% of treatment-naïve patients with CLL/SLL and del17p responded to treatment with zanubrutinib and venetoclax.
Jesus D. Gonzalez-Lugo, MD, and colleagues, presented the findings at the 2021 ASH Annual Meeting.
Results from the phase II IDIOME trial suggest that ivosidenib had good tolerability and significant efficacy.
These findings were shared at the 2021 ASH Annual Meeting by investigator Elsa Bernard, PhD.
The combination therapy was associated with increases in PFS rate and MRD negativity.
Researchers from a phase II study presented at the 2021 American Society of Hematology Annual Meeting reported that ...
Clonal hematopoiesis of indeterminate potential was associated with a reduced risk of Alzheimer's disease dementia.
According to data from the ZUMA-7 trial, the chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel (axi-cel) ...
Blood Cancers Today delivers the latest news, education, and information relevant to hematologic oncology patients and practices.
Sign up to receive Blood Cancers Today eNewsletters:
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.